New Study Will Explore Impact of Exercise on Pulmonary Hypertension PDF Print E-mail
Friday, 26 August 2011 11:53
For sufferers of Pulmonary Arterial Hypertension (PAH), maintaining healthy heart function isn't as simple as going for a jog every morning. Patients need to do all they can to slow damage to their heart, and exercise can improve potentially improve their quality of life.

On the other hand, the demands of pumping blood into stiff, large arteries and narrowed small arteries means that many PAH patients bear an increased risk of overexertion, which makes prescribing the correct amount of physical activity difficult.

Now, a University of Wisconsin-Madison biomedical engineer and colleagues hope to clear up that uncertainty in a new study seeking to quantify the impact of exercise on PAH patients.

Funded by a four-year, $2.5 million grant from the National Institutes of Health, Naomi Chesler, an associate professor of biomedical engineering at UW-Madison, will investigate the relationships between small artery narrowing, large artery stiffening and their interactions with the right side of the heart in patients with PAH.

"Most patients with pulmonary hypertension die from right heart failure, so even though the disease may be initiated in the small arteries of the lung, the impact on heart function is what's really critical," says Chesler.

Establishing how these factors relate to one another will allow Chesler and her team to develop a way of identifying PAH patients who can most benefit from regular exercise.

The objective will be finding identifiers that separate PAH patients who will benefit from exercise from those whose condition will worsen from it.

"We're trying to differentiate those people who have sufficiently good interactions between the heart and the lungs from those where the heart and lungs are not working well together," Chesler explains.

The study also builds upon Chesler's work on a previous NIH grant in which she researched how the presence of excess collagen, a fibrous protein found in connective tissues throughout the body, might contribute to pulmonary hypertension. "We're dovetailing our previous work on the role of collagen in large artery stiffening with new work on the impact of large artery stiffening on heart function. An important patient population in our new study is those with a collagen disorder," Chesler says.

Of particular interest in the study will be patients with scleroderma, or systemic sclerosis (SSc),a disease caused by excess collagen accumulation throughout the body, including blood vessels. Patients with SSc-related PAH don't have a lot of effective treatment options, but focusing on such patients in the study might identify their best treatment options.

Chesler's UW-Madison collaborators include Heidi Kellihan, clinical assistant professor in the School of Veterinary Medicine; Jim Runo, assistant professor of pulmonary medicine; Chris Francois, assistant professor of radiology; and Jens Eickhoff, biostatistics and medical informatics senior scientist. Mardi Gomberg-Maitland, an expert in pulmonary hypertension from the University of Chicago, is a consultant on the study, and Sanjiv Shah at Northwestern University will be conducting many of the patient studies, due to the large PAH patient population in Chicago.

Riechers, M (2011), "New Study Will Explore Impact of Exercise on Pulmonary Hypertension", University of Wisconsin-Madison;

 
More articles :

» Development of an Activity Index for Localized Scleroderma (Morphea)

E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, ItalyAnn Rheum Dis 2011;70(Suppl3):481Background: Morphea is a skin disorder characterized by fibrosis. It...

» June Is Scleroderma Awareness Month!

The month of June is Scleroderma Awareness Month around the world, and would like to encourage each and everyone of you, to become advocates by raising awareness and educating others about this often progressive, autoimmune connective tissue disease...

» New Genetic Path Targeted For Scleroderma Therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led by John Varga, MD, John and...

» Rituximab Shows Promise in Scleroderma

Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...

» Laughter Can Stimulate a Dull Appetite

Laughing can boost the appetite in the same way that does, a finding that could help people eat more when they're sick or depressed, a researcher says."The value of the research is that it may provide those who are health-care providers with new...

» Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates...